The Firm
Founded in 2002, Maxim Group is a leading full-service investment bank, securities and wealth management firm headquartered in mid-town Manhattan. We provide a comprehensive array of financial services including investment banking, global institutional sales, equity research, fixed income and derivative sales & trading, merchant capital, private wealth management, and prime brokerage services to a diverse range of corporate clients, institutional investors and high-net-worth individuals.
Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB).
Maxim Group is a member of:
FINRA
Financial Industry Regulatory Authority
NASDAQ
Stock market
Financial Industry Regulatory Authority
NASDAQ
Stock market
NYSE
Arca, Inc
SIPC
Securities Investor Protection Corporation
Arca, Inc
SIPC
Securities Investor Protection Corporation
Services
Investment Banking
Equity Research
Capital Markets
Merchant Capital
Wealth Management
Prime Brokerage
Locations
Corporate HeadquartersNew York, NY
300 Park Ave
16th Floor
New York, NY 10022
Tel 800 724 0761
Tel 212 895 3500
Fax 212 895 3555
16th Floor
New York, NY 10022
Tel 800 724 0761
Tel 212 895 3500
Fax 212 895 3555
South Florida Hub
Miami Beach, Florida
Miami Beach, Florida
555 Washington Avenue
Suite 320
Miami Beach, FL 33139
Fort Lauderdale,
Florida
Florida
1 East Broward Blvd
Suite 1430
Fort Lauderdale, FL 33301
Woodbury,
Long Island
Long Island
100 Crossways Park Dr West
Suite 207
Woodbury, NY 11797
Tel 800 537 6923
Tel 516 393 8300
Fax 516 364 1310
Red Bank,
New Jersey
New Jersey
246 Maple Avenue
Red Bank, NJ 07701
Tel 800 724 0761
Tel 732 784 1900
Fax 732 784 1982
Stamford,
Connecticut
Connecticut
700 Canal Street
Stamford, CT 06902
Latest Maxim Group News
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today
June 9, 2023
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today
June 9, 2023
Beneficient – a Financial Technology-Enabled Institution – Lists Shares Upon Successful Merger
Beneficient (“Ben,” “Beneficient” or the “Company”), a technology-enabled platform providing liquidity and related trust and
June 9, 2023